"Teplizumab for Prevention of Type 1 Diabetes In Relatives At-Risk"

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

November 30, 2018

Study Completion Date

June 30, 2019

Conditions
Autoantibody PositiveNon-diabetic Relatives at Risk for Type 1 DiabetesHigh RiskImpaired Glucose Tolerance
Interventions
DRUG

Teplizumab

intravenous infusions

DRUG

Placebo infusion

Placebo for Teplizumab

Trial Locations (19)

10032

Columbia University, New York

15201

University of Pittsburgh, Pittsburgh

32610

University of Florida, Gainesville

33136

University of Miami, Miami

33612

University of South Florida, Tampa

37232

Vanderbilt University, Nashville

46202

Indiana University, Indianapolis

55455

University of Minnesota, Minneapolis

64108

The Children's Mercy Hospital, Kansas City

77030

Baylor College of Medicine, Houston

80045

Barbara Davis Center for Childhood Diabetes/ University of Colorado, Denver

94143

University of California in San Francisco, San Francisco

University of California-San Francisco, San Francisco

94305

Stanford University, Stanford

982101

Benaroya Research Institute, Seattle

06519

Yale University School of Medicine, New Haven

75390-9072

University of Texas, Dallas

MSG-1X8

The Hospital for Sick Children, Toronto

Unknown

Forschergruppe Diabetes, Munich

Sponsors
All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

collaborator

National Center for Research Resources (NCRR)

NIH

collaborator

Juvenile Diabetes Research Foundation

OTHER

collaborator

American Diabetes Association

OTHER

lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH